Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185705 · ClinicalTrials.gov registry record · NA
Treatment of Insulin Resistance in Hypertensive, Obese Adolescents
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00185705: Clinical Trial NA study, sponsored by Stanford University.
NCT00185705 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00185705, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
In this study, we propose using telmisartan, an angiotensin II receptor antagonist with PPAR-gamma modulating activity, for a 12-week period to decrease blood pressure and insulin levels in obese, hypertensive children. Telmisartan is currently approved for treatment of adult hypertension. Recent adult studies, however, have shown telmisartan as an effective medication for lowering insulin levels and improving insulin sensitivity. We will enroll 30 obese adolescents, ages 10 to 18 years, and randomly assign half of the group to receive telmisartan and the other half to receive placebo (sugar-pill). We will obtain fasting glucose and insulin levels, as well as other markers for insulin sensitivity and cholesterol panel, at the beginning of the study, at each clinic visit in 4-week intervals, and at the end of the study. We will obtain an imaging study (computed tomography, CT scan) on 10 randomly selected study patients (5 from each group) to examine the distribution of fat tissue before and after treatment. Studies suggest that fat tissue in the subcutaneous tissue is less harmful that fat tissues surrounding internal organs, such as the liver. We will also provide nutritional handouts and exercise recommendations to each participant as a life-style intervention. Each participant will be given a diary to record his or her diet and exercise activities throughout the study.
Interventions
- DRUG Telmisartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00185705
The ClinicalTrials.gov registry entry for NCT00185705 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telmisartan is the first listed.
NCT00185705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00185705 about?
NCT00185705 is a clinical study titled "Treatment of Insulin Resistance in Hypertensive, Obese Adolescents". In this study, we propose using telmisartan, an angiotensin II receptor antagonist with PPAR-gamma modulating activity, for a 12-week period to decrease blood pressure and insulin levels in obese, hypertensive children. Telmisartan is currently approved for treatment of adult hypertension. Recent ad...
What is the current status of trial NCT00185705?
This trial is currently terminated. It is a NA study. The enrollment target is 30 participants. The study started on 2006-10. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00185705?
The interventions under investigation include: Telmisartan (DRUG).
Who is sponsoring clinical trial NCT00185705?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.